Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway-Reference-Cited by-同舟云学术

Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway

Published:2024-06-26 Issue:14 Volume:16 Page:11208-11223
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Zhang Yanbin¹,Zhang Tao²³⁴,Chen Long¹,Guo Zijun⁵,Jiang Xiaobing¹

Affiliation:

1. Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2. Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

3. Key Laboratory of Anesthesiology and Resuscitation, Huazhong University of Science and Technology, Ministry of Education, Wuhan 430022, China

4. Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

5. Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430062, China

Publisher

Impact Journals, LLC

Reference26 articles.

1. Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective.;Jaffe;Cancer Treat Res,2009

2. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.;Herold;Int J Mol Sci,2020

3. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.;Saunders;Br J Cancer,2010

4. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.;Gorlick;J Clin Oncol,2015

5. Mechanisms and insights into drug resistance in cancer.;Borden;Front Pharmacol,2013